Zepres Plus (enalapril maleate + hydrochlorothiazide..): Uses, Dosage & Side Effects

What it's for (Indications)

Enalapril maleate and hydrochlorothiazide is a fixed-dose combination medication primarily indicated for the treatment of essential hypertension.
This combination therapy is particularly suitable for patients whose blood pressure is not adequately controlled with monotherapy using either an angiotensin-converting enzyme (ACE) inhibitor (like enalapril) or a thiazide diuretic (like hydrochlorothiazide) alone.
It is also indicated as a substitution therapy for patients whose blood pressure is stable on the individual components given concurrently at the same doses.
The rationale behind this combination lies in the synergistic antihypertensive effects of its two components; enalapril, by inhibiting the renin-angiotensin-aldosterone system, and hydrochlorothiazide, by increasing renal excretion of sodium and water.
This dual action leads to more effective blood pressure reduction and can help mitigate some of the compensatory mechanisms that arise when either agent is used alone.
It is not generally recommended for initial therapy in all hypertensive patients due to the fixed-dose nature, as initial dose titration of individual components is often preferred to optimize treatment and minimize side effects.

Dosage Information

Type	Guideline
Standard	The dosage of enalapril maleate and hydrochlorothiazide must be individualized based on the patient's blood pressure response and tolerance, with careful consideration of the patient's renal function, volume status, and concomitant medications. This fixed-dose combination is not intended for initial therapy where precise titration of individual components is necessary. Instead, it is typically initiated after a patient's optimal dose of enalapril and hydrochlorothiazide has been established through separate titrations, or when monotherapy with either agent has proven insufficient. The usual recommended dose is one tablet once daily, typically administered in the morning. Dosage adjustments may be required in patients with renal impairment, and the combination is contraindicated in severe renal dysfunction (creatinine clearance < 30 mL/min). Close monitoring for signs of hypotension, particularly at the initiation of therapy or after dosage increases, is crucial, especially in volume-depleted patients. Regular assessment of serum electrolytes and renal function is also essential throughout treatment.

Type

Guideline

Standard

The dosage of enalapril maleate and hydrochlorothiazide must be individualized based on the patient's blood pressure response and tolerance, with careful consideration of the patient's renal function, volume status, and concomitant medications. This fixed-dose combination is not intended for initial therapy where precise titration of individual components is necessary. Instead, it is typically initiated after a patient's optimal dose of enalapril and hydrochlorothiazide has been established through separate titrations, or when monotherapy with either agent has proven insufficient. The usual recommended dose is one tablet once daily, typically administered in the morning. Dosage adjustments may be required in patients with renal impairment, and the combination is contraindicated in severe renal dysfunction (creatinine clearance < 30 mL/min). Close monitoring for signs of hypotension, particularly at the initiation of therapy or after dosage increases, is crucial, especially in volume-depleted patients. Regular assessment of serum electrolytes and renal function is also essential throughout treatment.

Safety & Warnings

Common Side Effects

As a combination product, potential side effects encompass those associated with both enalapril maleate and hydrochlorothiazide.
Common side effects for enalapril include a persistent dry cough, dizziness, fatigue, and headache, primarily due to its ACE inhibitor properties.
Orthostatic hypotension can also occur, particularly with the initial dose.
Less common but more serious enalapril-related adverse effects include angioedema (swelling of the face, lips, tongue, or larynx), hyperkalemia, and renal dysfunction.
For hydrochlorothiazide, common side effects involve electrolyte imbalances such as hypokalemia, hyponatremia, hypomagnesemia, and hypercalcemia.
Other frequent adverse effects include dizziness, lightheadedness, increased urination, hyperglycemia, and hyperuricemia.
Serious, albeit rare, side effects associated with hydrochlorothiazide can include pancreatitis, blood dyscrasias, acute myopia, and secondary angle-closure glaucoma.
Patients should be advised to report any unusual symptoms promptly to their healthcare provider.
Due to the diuretic component, photosensitivity is also a potential concern.

Serious Warnings

Black Box Warning: WARNING: FETAL TOXICITY. When pregnancy is detected, discontinue enalapril maleate and hydrochlorothiazide as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Several critical warnings are associated with enalapril maleate and hydrochlorothiazide.
Angioedema, involving swelling of the face, extremities, lips, tongue, glottis, and/or larynx, can occur at any time during ACE inhibitor treatment and can be life-threatening.
If angioedema occurs, the medication must be immediately discontinued, and appropriate medical intervention initiated.
Patients, especially Black patients, are at a higher risk.
Symptomatic hypotension, particularly in volume-depleted individuals (e.
g.
, those on high-dose diuretics), severe congestive heart failure, or those undergoing dialysis, requires close monitoring, especially with the initial dose.
Renal impairment can be exacerbated by ACE inhibitors, particularly in patients with severe heart failure or bilateral renal artery stenosis; therefore, regular assessment of renal function is mandatory.
This combination is contraindicated in severe renal impairment.
Hyperkalemia is a risk, especially in patients with renal dysfunction, diabetes, or those receiving potassium-sparing diuretics or supplements.
The medication is contraindicated in pregnancy, particularly during the second and third trimesters, due to risks of fetal injury and death.
Hydrochlorothiazide can cause electrolyte imbalances and should be used with caution in patients with a history of gout or diabetes.
Acute transient myopia and acute angle-closure glaucoma have been reported with hydrochlorothiazide, requiring immediate discontinuation.

How it Works (Mechanism of Action)

Enalapril maleate and hydrochlorothiazide combine two distinct pharmacological agents to achieve comprehensive blood pressure control. Enalapril maleate, an angiotensin-converting enzyme (ACE) inhibitor, acts by blocking the conversion of angiotensin I to angiotensin II. Angiotensin II is a potent vasoconstrictor and a key stimulator of aldosterone secretion. By reducing angiotensin II levels, enalapril causes vasodilation, thereby decreasing peripheral vascular resistance, and reduces aldosterone production, leading to decreased sodium and water retention. It also inhibits the degradation of bradykinin, a vasodilator, further contributing to its hypotensive effect. Hydrochlorothiazide, a thiazide diuretic, exerts its primary action in the distal convoluted tubule of the kidney. It inhibits the active reabsorption of sodium and chloride ions, leading to increased excretion of sodium, chloride, and water. This diuretic action reduces plasma volume and, consequently, cardiac output, contributing to its antihypertensive effect. Long-term use of thiazide diuretics may also involve a direct vasodilatory effect. The combination of enalapril and hydrochlorothiazide provides a synergistic antihypertensive effect; enalapril counteracts the diuretic-induced activation of the renin-angiotensin-aldosterone system and potassium loss, while hydrochlorothiazide enhances the blood pressure-lowering efficacy of enalapril, leading to a more robust and sustained antihypertensive response compared to either agent used alone.